Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt No Debt
MELA's Cash to Debt is ranked higher than
93% of the 291 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.74 vs. MELA: No Debt )
MELA' s 10-Year Cash to Debt Range
Min: No Debt   Max: No Debt
Current: No Debt

Equity to Asset 0.59
MELA's Equity to Asset is ranked higher than
65% of the 285 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.63 vs. MELA: 0.59 )
MELA' s 10-Year Equity to Asset Range
Min: 0.59   Max: 1
Current: 0.59

0.59
1
F-Score: 2
Z-Score: -19.62
M-Score: -4.87
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -4502.61
MELA's Operating margin (%) is ranked lower than
57% of the 287 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 9.44 vs. MELA: -4502.61 )
MELA' s 10-Year Operating margin (%) Range
Min: -8174.46   Max: -869.05
Current: -4502.61

-8174.46
-869.05
Net-margin (%) -4841.04
MELA's Net-margin (%) is ranked lower than
57% of the 287 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 7.65 vs. MELA: -4841.04 )
MELA' s 10-Year Net-margin (%) Range
Min: -8155.76   Max: -1085.71
Current: -4841.04

-8155.76
-1085.71
ROE (%) -312.78
MELA's ROE (%) is ranked lower than
57% of the 283 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 8.68 vs. MELA: -312.78 )
MELA' s 10-Year ROE (%) Range
Min: -312.78   Max: -36.85
Current: -312.78

-312.78
-36.85
ROA (%) -183.61
MELA's ROA (%) is ranked lower than
57% of the 290 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.24 vs. MELA: -183.61 )
MELA' s 10-Year ROA (%) Range
Min: -451.39   Max: -35.09
Current: -183.61

-451.39
-35.09
ROC (Joel Greenblatt) (%) -523.86
MELA's ROC (Joel Greenblatt) (%) is ranked lower than
53% of the 288 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 22.38 vs. MELA: -523.86 )
MELA' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -3690.29   Max: -51.95
Current: -523.86

-3690.29
-51.95
EBITDA Growth (%) -13.50
MELA's EBITDA Growth (%) is ranked higher than
59% of the 210 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 6.40 vs. MELA: -13.50 )
MELA' s 10-Year EBITDA Growth (%) Range
Min: 0   Max: -1.1
Current: -13.5

EPS Growth (%) -10.30
MELA's EPS Growth (%) is ranked higher than
62% of the 220 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.90 vs. MELA: -10.30 )
MELA' s 10-Year EPS Growth (%) Range
Min: -28.9   Max: 34.6
Current: -10.3

-28.9
34.6
» MELA's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

MELA Guru Trades in

MELA Guru Trades in

MELA Guru Trades in

Q2 2012

MELA Guru Trades in Q2 2012

George Soros Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with MELA

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
George Soros 2012-06-30 Sold Out 0.01%$2.51 - $4.74 $ 0.54-85%0
George Soros 2012-03-31 Reduce -80%0.13%$3.21 - $4.82 $ 0.54-87%200000
George Soros 2011-12-31 New Buy0.16%$3.5 - $6.62 $ 0.54-89%1000000
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 3.10
MELA's P/B is ranked higher than
58% of the 278 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.77 vs. MELA: 3.10 )
MELA' s 10-Year P/B Range
Min: 1.52   Max: 4.91
Current: 3.1

1.52
4.91
P/S 43.29
MELA's P/S is ranked lower than
91% of the 292 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.60 vs. MELA: 43.29 )
MELA' s 10-Year P/S Range
Min: 41   Max: 211
Current: 43.29

41
211
EV-to-EBIT 16.10
MELA's EV-to-EBIT is ranked higher than
69% of the 247 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 18.32 vs. MELA: 16.10 )
MELA' s 10-Year EV-to-EBIT Range
Min: 0   Max: 0
Current: 16.1

Valuation & Return

vs
industry
vs
history
Price/Net Current Asset Value 27.00
MELA's Price/Net Current Asset Value is ranked lower than
68% of the 118 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 13.00 vs. MELA: 27.00 )
MELA' s 10-Year Price/Net Current Asset Value Range
Min: 2.94   Max: 32
Current: 27

2.94
32
Price/Tangible Book 3.20
MELA's Price/Tangible Book is ranked higher than
73% of the 232 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.80 vs. MELA: 3.20 )
MELA' s 10-Year Price/Tangible Book Range
Min: 2.66   Max: 7.64
Current: 3.2

2.66
7.64
Price/Median PS Value 0.70
MELA's Price/Median PS Value is ranked higher than
91% of the 268 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.10 vs. MELA: 0.70 )
MELA' s 10-Year Price/Median PS Value Range
Min: 0.76   Max: 2.13
Current: 0.7

0.76
2.13
Forward Rate of Return (Yacktman) -125.74
MELA's Forward Rate of Return (Yacktman) is ranked lower than
53% of the 217 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.90 vs. MELA: -125.74 )
MELA' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 0   Max: 0
Current: -125.74

Business Description

Industry: Medical Instruments & Equipment » Medical Instruments & Supplies
Compare:WST, BAX, COV, TMO, COO » details
Traded in other countries:E2O.Germany
MELA Sciences, Inc. commenced operations in December 1989 as a New York corporation, re-incorporated as a Delaware corporation in September 1997, and changed its name from Electro-Optical Sciences, Inc. to MELA Sciences, Inc. April 30, 2010. The Company is a medical device company engaged in designing and development of a non-invasive, point-of-care instrument to assist in the early diagnosis of melanoma. The Company's flagship product, MelaFind is a non-invasive and objective computer vision system intended to aid in the early detection of melanoma. The Company offers MelaFind to dermatologists as a non-invasive, point-of-care service that provides additional information about specific moles during a skin exam, which have one or more clinical or historical characteristics of melanoma, before a final decision to biopsy has been rendered. MelaFind(R) acquires and displays multi-spectral (from blue to near infrared) digital images of pigmented skin lesions and uses automatic image analysis and statistical pattern recognition to help identify lesions to be considered for biopsy to rule out melanoma. The Company's operations are confined to one business segment: the design, development and commercialization of MelaFind. The company's product MelaFind is regulated as a medical device and is subject to extensive regulation by the FDA and other regulatory authorities in the U.S.

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Hide